Drug Profile
TKM Ebola
Alternative Names: Ebola SNALP; siEbola-2; siRNA Ebola virus infection therapeutic - Arbutus Biopharma; TKM-100201; TKM-100802; TKM-Ebola; TKM-Ebola KikwitLatest Information Update: 12 Oct 2021
Price :
$50
*
At a glance
- Originator Protiva Biotherapeutics
- Developer Arbutus Biopharma
- Class Antivirals; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Ebola virus infections
Highest Development Phases
- Discontinued Ebola virus infections
Most Recent Events
- 12 Oct 2021 Discontinued - Phase-I for Ebola virus infections in USA (IV) (Arbutus Biopharma pipeline, October 2021)
- 24 Oct 2016 Phase-I development suspended for Ebola virus infections in USA (Arbutus BioPharma pipeline; October 2016)
- 12 Oct 2016 TKM Ebola is available for licensing as of 12 Oct 2016. http://arbutusbio.com/partners/partnering-licensing-opportunities.php